Different action on dopamine catabolic pathways of two endogenous 1,2,3,4-tetrahydroisoquinolines with similar antidopaminergic properties

被引:77
作者
Antkiewicz-Michaluk, L
Michaluk, J
Mokrosz, M
Romanska, I
Lorenc-Koci, E
Ohta, S
Vetulani, J
机构
[1] Polish Acad Sci, Inst Pharmacol, PL-31343 Krakow, Poland
[2] Hiroshima Univ, Sch Med, Inst Pharmaceut Sci, Hiroshima 734, Japan
关键词
DOPAC; dopamine catabolism; dopamine metabolism; 3MT; HVA; functional antidopaminergic activity;
D O I
10.1046/j.1471-4159.2001.00391.x
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The effect of single and multiple 1-methyl-1,2,3,4-tetrahydroisoquinoline (1MeTIQ) and 1-benzyl-1,2,3,4-tetrahydroisoquinoline (1BnTIQ) administration on concentrations of dopamine and its metabolites: homovanillic acid (HVA) and 3,4-dihydroxyphenylacetic acid (DOPAC) and 3-methoxytyramine (3MT) in three brain areas was studied HPLC with electrochemical detection in Wistar rats. The rate of dopamine catabolism in the striatum along the N-oxidative and O-methylation pathways was assessed by calculation of the ratio of appropriate metabolites to dopamine concentration. In addition, the spontaneous and apomorphine-stimulated locomotor activity, and muscle rigidity was studied after acute administration of 1MeTIQ and 1BnTIQ. We have found that 1MeTIQ did not change the level of dopamine and HVA in all investigated structures both after a single and chronic administration. However, the levels of intermediary dopamine metabolites, DOPAC and 3MT, were distinctly affected. The level of DOPAC was strongly depressed (by 60-70%) while the level of extraneuronal matabolite 3MT was significantly elevated (by 170-200%). In contrast to 1MeTIQ, 1BnTIQ depressed the level of dopamine (by approximately 60%) and increased the level of total metabolite, HVA. (by 40%) especially in the striatum, but the levels of DOPAC and 3MT remained unchanged. The paper has shown that 1MeTIQ and 1BnTIQ produced different effects on dopamine catabolism. Potential neuroprotective compound 1MeTIQ did not change the rate of total dopamine catabolism, it strongly inhibited the monoamine oxidase (MAO)-dependent catabolic pathway and significantly activated the catechol-O-methyltransferase (COMT)-dependent O methylation. In contrast 1BnTIQ, a compound with potential neurotoxic activity, produced the significant increase of the rate of dopamine metabolism with strong activation of the oxidative MAO-dependent catabolic pathway. Interestingly, both compounds produced similar antidopaminergic functional effects: antagonism of apomorphine hyperactivity and induction of muscle rigidity. The results may explain the biochemical basis of the neuroprotective and of the neurotoxic properties endogenous brain tetrahydroisoquinoline derivatives.
引用
收藏
页码:100 / 108
页数:9
相关论文
共 35 条
  • [1] OXYGEN FREE-RADICALS AND PARKINSONS-DISEASE
    ADAMS, JD
    ODUNZE, IN
    [J]. FREE RADICAL BIOLOGY AND MEDICINE, 1991, 10 (02) : 161 - 169
  • [2] [Anonymous], [No title captured]
  • [3] Antkiewicz-Michaluk L, 1999, NEUROSCI RES COMMUN, V25, P97, DOI 10.1002/(SICI)1520-6769(199909/10)25:2<97::AID-NRC5>3.0.CO
  • [4] 2-K
  • [5] Neurochemical changes induced by acute and chronic administration of 1,2,3,4-tetrahydroisoquinoline and salsolinol in dopaminergic structures of rat brain
    Antkiewicz-Michaluk, L
    Romañska, I
    Papla, I
    Michaluk, J
    Bakalarz, M
    Vetulani, J
    Krygowska-Wajs, A
    Szczudlik, A
    [J]. NEUROSCIENCE, 2000, 96 (01) : 59 - 64
  • [6] Antidopaminergic effects of 1,2,3,4-tetrahydroisoquinoline and salsolinol
    Antkiewicz-Michaluk, L
    Michaluk, J
    Romanska, I
    Papla, I
    Vetulani, J
    [J]. JOURNAL OF NEURAL TRANSMISSION, 2000, 107 (8-9) : 1009 - 1019
  • [7] Increase in salsolinol level in the cerebrospinal fluid of parkinsonian patients is related to dementia: Advantage of a new high-performance liquid chromatography methodology
    AntkiewiczMichaluk, L
    KrygowskaWajs, A
    Szczudlik, A
    Romanska, I
    Vetulani, J
    [J]. BIOLOGICAL PSYCHIATRY, 1997, 42 (06) : 514 - 518
  • [8] MPTP MECHANISMS OF NEUROTOXICITY AND THEIR IMPLICATIONS FOR PARKINSONS-DISEASE
    GERLACH, M
    RIEDERER, P
    PRZUNTEK, H
    YOUDIM, MBH
    [J]. EUROPEAN JOURNAL OF PHARMACOLOGY-MOLECULAR PHARMACOLOGY SECTION, 1991, 208 (04): : 273 - 286
  • [9] Animal models of Parkinson's disease: An empirical comparison with the phenomenology of the disease in man
    Gerlach, M
    Riederer, P
    [J]. JOURNAL OF NEURAL TRANSMISSION, 1996, 103 (8-9) : 987 - 1041
  • [10] GINOS JZ, 1979, J PHARMACOL EXP THER, V209, P79